Cilazapril
Code | Size | Price |
---|
TAR-T20167-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T20167-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Cilazapril is an angiotensin-converting enzyme inhibitor. It has been researched for mild to moderate essential hypertension.
CAS:
88768-40-5
Formula:
C22H31N3O5
Molecular Weight:
417.506
Purity:
0.98
SMILES:
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O
References
1. Stanisz BJ, Paszun SK, Zalewska A. Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms. Acta Pol Pharm. 2014 Jul-Aug;71(4):661-6. PubMed PMID: 25272892.
2. Paszun SK, Stanisz BJ, Gradowska A. Cilazapril stability in the presence of hydrochlorothiazide in model mixtures and fixed dose combination. Acta Pol Pharm. 2013 Nov-Dec;70(6):1079-85. PubMed PMID: 24383331.
3. Narayanam M, Sahu A, Singh S. Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril. J Pharm Biomed Anal. 2015;111:190-203. doi: 10.1016/j.jpba.2015.03.038. Epub 2015 Apr 3. PubMed PMID: 25890215.
4. Kolocouri F, Dotsikas Y, Apostolou C, Kousoulos C, Soumelas GS, Loukas YL. Advantages of automation in plasma sample preparation prior to HPLC/MS/MS quantification: application to the determination of cilazapril and cilazaprilat in a bioequivalence study. J AOAC Int. 2011 May-Jun;94(3):758-64. PubMed PMID: 21797003.